On 27 Jan 2020, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) spotted trading -64.82% off 52-week high price. On the other end, the stock has been noted 28.89% away from the low price over the last 52-weeks. The stock changed -11.59% to recent value of $2.9. The stock transacted 22269 shares during most recent day however it has an average volume of 21.3K shares. The company has 20.29M of outstanding shares and 11.15M shares were floated in the market.
Alpine Immune Sciences, Inc. (ALPN) recently stated a corporate update and financial results for the third quarter ended September 30, 2019.
“The third quarter of 2019 included several important milestones for Alpine, highlighted by completion of enrollment in our Phase 1 study in healthy volunteers for our lead program, ALPN-101,” stated Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. “We believe ALPN-101 has the potential to deliver importantly differentiated efficacy outcomes across a range of inflammatory and autoimmune diseases. We look forward to highlighting our upcoming Phase 1/2 BALANCE study of ALPN-101 during an oral presentation at the ASH yearly meeting next month.”
Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Alpine recorded a net loss of $11.5M and $12.1M for the third quarters ended September 30, 2019 and 2018, respectively, and $35.7M and $25.4M for the nine months ended September 30, 2019 and 2018, respectively.
Research and development expenses for the third quarter ended September 30, 2019 were $9.5M contrast to $10.5M for the third quarter ended September 30, 2018. For the nine months ended September 30, 2019 and 2018, research and development expenses were $30.0M and $20.0M, respectively. The company expects a continued increase to research and development activities to support the clinical advancement of its ALPN-101 and ALPN-202 programs.
General and administrative expenses for the third quarter ended September 30, 2019 were $2.5M contrast to $1.9M for the third quarter ended September 30, 2018. For the nine months ended September 30, 2019 and 2018, general and administration expenses were $7.4M and $5.8M, respectively. The increase was primarily attributable to professional and legal services and a raise in facility costs to support the growth and expansion of our business.
Its earnings per share (EPS) expected to touch remained -113.90% for this year while earning per share for the next 5-years is expected to reach at # ref. ALPN has a gross margin of # ref and an operating margin of # ref while its profit margin remained # ref for the last 12 months. According to the most recent quarter its current ratio was 3.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of -22.29% from the mean of 20 days, -14.15% from mean of 50 days SMA and performed -31.46% from mean of 200 days price. Company’s performance for the week was -13.95%, -21.20% for month and YTD performance remained -24.48%.